DK3303616T3 - Fremgangsmåder til prognose af prostatakræft - Google Patents

Fremgangsmåder til prognose af prostatakræft Download PDF

Info

Publication number
DK3303616T3
DK3303616T3 DK16727361.4T DK16727361T DK3303616T3 DK 3303616 T3 DK3303616 T3 DK 3303616T3 DK 16727361 T DK16727361 T DK 16727361T DK 3303616 T3 DK3303616 T3 DK 3303616T3
Authority
DK
Denmark
Prior art keywords
prostate
procedures
cancer
prostate cancer
prostate prostate
Prior art date
Application number
DK16727361.4T
Other languages
English (en)
Inventor
Ralf Hoffmann
Biezen - Timmermans Eveline Den
Strijp Dianne Arnoldina Margaretha Wilhelmina Van
Brussel Anne Godefrida Catharina Van
Janneke Wrobel
Zon Joannes Baptist Adrianus Dionisius Van
De Inda Márcia Alves
Original Assignee
Koninklijke Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv filed Critical Koninklijke Philips Nv
Application granted granted Critical
Publication of DK3303616T3 publication Critical patent/DK3303616T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
DK16727361.4T 2015-05-29 2016-05-26 Fremgangsmåder til prognose af prostatakræft DK3303616T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15169788 2015-05-29
PCT/EP2016/061886 WO2016193110A1 (en) 2015-05-29 2016-05-26 Methods of prostate cancer prognosis

Publications (1)

Publication Number Publication Date
DK3303616T3 true DK3303616T3 (da) 2021-03-01

Family

ID=53298161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16727361.4T DK3303616T3 (da) 2015-05-29 2016-05-26 Fremgangsmåder til prognose af prostatakræft

Country Status (10)

Country Link
US (2) US11827938B2 (da)
EP (1) EP3303616B1 (da)
JP (1) JP6745820B2 (da)
KR (1) KR20180082328A (da)
CN (1) CN108738329A (da)
BR (1) BR112017025255B1 (da)
DK (1) DK3303616T3 (da)
ES (1) ES2861316T3 (da)
RU (1) RU2760577C2 (da)
WO (1) WO2016193110A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3502280A1 (en) 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
EP3546598A1 (en) 2018-03-29 2019-10-02 Koninklijke Philips N.V. Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables
WO2020102374A1 (en) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Targeting of makap-pde4d3 complexes in neurodegenerative disease
GB2626699B (en) * 2019-05-08 2024-11-20 Oxford BioDynamics PLC Chromosome Conformation Markers of Prostate Cancer and Lymphoma
EP3885453A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on dna repair genes
TR202007444A1 (tr) * 2020-05-13 2021-11-22 Aselsan Elektronik Sanayi Ve Ticaret As Hem manyeti̇k parçacik görüntüleme hem de manyeti̇k rezonans görüntüleme gerçekleşti̇ri̇lmesi̇ne i̇mkan sunan bi̇r terti̇bat ve bu terti̇bati i̇çeren bi̇r ci̇haz
EP3960876A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes
EP3960877A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject
JP2023550009A (ja) 2020-11-06 2023-11-30 ヴェリリー ライフ サイエンシズ エルエルシー 前立腺がん転帰の人工知能予測
WO2023129947A2 (en) * 2021-12-29 2023-07-06 Salk Institute For Biological Studies Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d3
CN116103395B (zh) * 2022-09-05 2025-09-09 南京鼓楼医院 用于胃癌诊断的circRNA标志物及诊断试剂盒
EP4574997A1 (en) * 2023-12-19 2025-06-25 Koninklijke Philips N.V. Prediction of an outcome of a prostate cancer subject
EP4620461A1 (en) 2024-03-22 2025-09-24 Koninklijke Philips N.V. Treatment of prostate cancer by inhibiting short pde4d isoforms
CN119932197B (zh) * 2025-04-09 2025-06-13 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
WO2004028341A2 (en) * 2001-03-19 2004-04-08 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
US20050164220A1 (en) 2001-03-19 2005-07-28 Decode Genetics Ehf. Susceptibility gene for human stroke: method of treatment
US20030220273A1 (en) 2002-05-15 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of phosphodiesterase 4D expression
EP1471153A3 (en) 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2004090157A1 (en) 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag The use of pde4d in the screening for medicaments against atherosclerosis
CA2627230C (en) * 2005-10-25 2016-08-16 F. Hoffmann-La Roche Ag Association of pde4d allelic variants with stroke
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
BRPI1007704A2 (pt) 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
RU2592668C2 (ru) 2009-05-12 2016-07-27 Конинклейке Филипс Электроникс Н.В. Фосфодиэстераза 9а в качестве маркера злокачественной опухоли предстательной железы
CN102549167B (zh) 2009-05-12 2017-04-26 皇家飞利浦电子股份有限公司 作为前列腺癌标志物的磷酸二酯酶4d7
EP2611941A4 (en) * 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
MX351626B (es) * 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
CN102603676B (zh) 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂

Also Published As

Publication number Publication date
JP6745820B2 (ja) 2020-08-26
WO2016193110A1 (en) 2016-12-08
JP2018521637A (ja) 2018-08-09
BR112017025255A2 (en) 2018-08-07
US11198909B2 (en) 2021-12-14
RU2017146409A3 (da) 2020-03-27
BR112017025255B1 (pt) 2024-02-27
US11827938B2 (en) 2023-11-28
US20170073778A1 (en) 2017-03-16
RU2017146409A (ru) 2019-07-02
RU2760577C2 (ru) 2021-11-29
EP3303616A1 (en) 2018-04-11
CN108738329A (zh) 2018-11-02
EP3303616B1 (en) 2021-01-06
KR20180082328A (ko) 2018-07-18
ES2861316T3 (es) 2021-10-06
US20180148795A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
IL255261A0 (en) Methods for treating cancer
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3478286T3 (da) Fremgangsmåder til behandling af ovariecancer
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3377516T3 (da) Sammensætning til behandling af cancer
MA43259A (fr) Liants ctla4
IL258684A (en) Combination therapy for treating malignancies
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3393372T3 (da) System til forøgelse af at kropslumens
PL3197456T3 (pl) Leczenie nowotworów
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3302063T3 (da) Fremgangsmåde til stimulering af frø
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3518932T3 (da) Behandling af prostatacancer
DK3353177T3 (da) Tricykliske heterocykler til behandling af cancer
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3089749T3 (da) Kombinerede præparater til behandling af cancer